143 related articles for article (PubMed ID: 21289942)
21. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
22. [Cervical cancer screening: past--present--future].
Breitenecker G
Pathologe; 2009 Dec; 30 Suppl 2():128-35. PubMed ID: 19756616
[TBL] [Abstract][Full Text] [Related]
23. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
24. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
25. MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial.
Kitchener HC; Blanks R; Cubie H; Desai M; Dunn G; Legood R; Gray A; Sadique Z; Moss S;
Health Technol Assess; 2011 Jan; 15(3):iii-iv, ix-xi, 1-170. PubMed ID: 21266159
[TBL] [Abstract][Full Text] [Related]
26. [Performance of vaginal self-sampling high-risk HPV genotyping as primary and combining cytology or viral load as secondary in cervical cancer screening].
Guo CL; Luo HX; Wang C; Qu XF; Yang B; Belinson JL; Du H; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2021 Apr; 56(4):271-279. PubMed ID: 33902239
[No Abstract] [Full Text] [Related]
27. Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England.
Bains I; Choi YH; Soldan K; Jit M
Int J Gynecol Cancer; 2019 Apr; ():. PubMed ID: 31018938
[TBL] [Abstract][Full Text] [Related]
28. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.
Popadiuk C; Gauvreau CL; Bhavsar M; Nadeau C; Asakawa K; Flanagan WM; Wolfson MC; Coldman AJ; Memon S; Fitzgerald N; Lacombe J; Miller AB
Curr Oncol; 2016 Feb; 23(Suppl 1):S56-63. PubMed ID: 26985148
[TBL] [Abstract][Full Text] [Related]
29. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus testing and conventional pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former soviet union.
Syrjänen S; Shabalova IP; Petrovichev N; Kozachenko VP; Zakharova T; Pajanidi J; Podistov JI; Chemeris G; Sozaeva LG; Lipova EV; Tsidaeva I; Ivanchenko OG; Pshepurko AA; Zakharenko S; Nerovjna R; Kljukina LB; Erokhina OA; Branovskaja MF; Nikitina M; Grunberga V; Grunberg A; Juschenko A; Tosi P; Cintorino M; Santopietro R; Syrjänen KJ
J Low Genit Tract Dis; 2002 Apr; 6(2):97-110. PubMed ID: 17051008
[TBL] [Abstract][Full Text] [Related]
31. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
Cox JT;
Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
[TBL] [Abstract][Full Text] [Related]
32. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
33. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
[TBL] [Abstract][Full Text] [Related]
34. [Role of cytological test for cervices to identify human papillomavirus in the screening program on serious cervical lesion].
Wang GP; Li RZ; Wu LN; Li J; Liu ZH; Wang C; Zhou YQ; Weng LM; Wu RF
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):626-30. PubMed ID: 19957634
[TBL] [Abstract][Full Text] [Related]
35. A systematic review of economic evaluations of cervical cancer screening methods.
Sefuthi T; Nkonki L
Syst Rev; 2022 Aug; 11(1):162. PubMed ID: 35945642
[TBL] [Abstract][Full Text] [Related]
36. Two Years of Cytology and HPV Co-Testing in Germany: Initial Experience.
Xhaja A; Ahr A; Zeiser I; Ikenberg H
Geburtshilfe Frauenheilkd; 2022 Dec; 82(12):1378-1386. PubMed ID: 36467972
[No Abstract] [Full Text] [Related]
37. Current Status and Future Perspectives of Molecular Prevention Strategies for Cervical Cancers.
Krishnamurthy A; Ramshankar V
Indian J Surg Oncol; 2020 Dec; 11(4):752-761. PubMed ID: 33299288
[TBL] [Abstract][Full Text] [Related]
38. Adherence to triage among women with HPV-positive self-collection: a study in a middle-low income population in Argentina.
Paolino M; Gago J; Pera AL; Cinto O; Thouyaret L; Arrossi S
Ecancermedicalscience; 2020; 14():1138. PubMed ID: 33281930
[TBL] [Abstract][Full Text] [Related]
39. New insights into cervical cancer screening.
Boone JD; Erickson BK; Huh WK
J Gynecol Oncol; 2012 Oct; 23(4):282-7. PubMed ID: 23094132
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
